Hjem
Centre for Cancer Biomarkers
JUSS – CCBIO Junior Scientist Symposium

CCBIO Junior Scientist Symposium

Velkommen til det siste CCBIO Junior Scientist Symposium i vårsemesteret i 2022!

Owl pointing to the symposium date.
Foto/ill.:
CCBIO/Colourbox

Hovedinnhold

Dear all

We are happy to welcome you all to the last CCBIO Junior Scientist Symposium for this semester, May 12th, 2022. We are very excited that Henriette Christie Ertsås (Forskning Til Folket) will be our keynote presenter this time, asking if scientific discovery can ever be compatible with the reigning publishing model, without science and society falling prey. Local junior researchers will present topics related to breast cancer, including how AGR2 relates to aggressive features and the relationship between tumor hypoxia and metastasis. And maybe we will learn where to find fantastic antibodies against the influenza virus? 

We are very pleased to be able to meet in person, but the symposium will also be open for digital attendance. Please register within May 9th at 11.00 for those of you who want to attend in person. There is no registration deadline for digital attendance. 

Postdocs Maria Lie Lotsberg and Hanna Dillekås are coordinators of the junior seminars from October 2021, and are planning and chairing these meetings. 

Where: A hybrid solution with onsite participation in Auditorium Glasblokkene (Haukelandsbakken 15), or in Zoom. Zoom link will be sent to those who register for online participation.

When: May 12, 2022, 09:00-12:45

Registration: at this link

Who: Open for all interested.

Program:

09.00-09.15: Introduction

09.15-10.00: “Of course, you would never publish in a predatory journal... or would you?” Keynote lecture by Henriette Christie Ertsås

10.00-10.35: Coffee break

10.35-11.00: “Low Anterior gradient 2 (AGR2) relates to aggressive tumor features in breast cancer” Amalie Fagerli Tegnander

11.00-11.45: Lunch (free of charge, register within May 9th at 11.00)

11.45-12.10: “Suppression of breast cancer metastasis by targeting tumour hypoxia?” Maria Kathrine Tveitarås

12.10-12.35 “Fantastic antibodies and where to find them” Lena Hansen 

12.35-12.45: Concluding remarks